Published in Infect Immun on December 01, 2005
The chlamydial plasmid-encoded protein pgp3 is secreted into the cytosol of Chlamydia-infected cells. Infect Immun (2008) 1.97
Pathogenesis of genital tract disease due to Chlamydia trachomatis. J Infect Dis (2010) 1.87
Caspase-1 contributes to Chlamydia trachomatis-induced upper urogenital tract inflammatory pathologies without affecting the course of infection. Infect Immun (2007) 1.85
Cationic liposomes formulated with synthetic mycobacterial cordfactor (CAF01): a versatile adjuvant for vaccines with different immunological requirements. PLoS One (2008) 1.65
Intranasal vaccination with a secreted chlamydial protein enhances resolution of genital Chlamydia muridarum infection, protects against oviduct pathology, and is highly dependent upon endogenous gamma interferon production. Infect Immun (2006) 1.63
Chlamydia trachomatis polymorphic membrane protein D is a species-common pan-neutralizing antigen. Proc Natl Acad Sci U S A (2006) 1.63
Characterization of Francisella tularensis outer membrane proteins. J Bacteriol (2006) 1.59
The hypothetical protein CT813 is localized in the Chlamydia trachomatis inclusion membrane and is immunogenic in women urogenitally infected with C. trachomatis. Infect Immun (2006) 1.47
A MyD88-dependent early IL-17 production protects mice against airway infection with the obligate intracellular pathogen Chlamydia muridarum. J Immunol (2009) 1.39
Chlamydia trachomatis native major outer membrane protein induces partial protection in nonhuman primates: implication for a trachoma transmission-blocking vaccine. J Immunol (2009) 1.33
Vaccination against Chlamydia genital infection utilizing the murine C. muridarum model. Infect Immun (2010) 1.33
Native outer membrane proteins protect mice against pulmonary challenge with virulent type A Francisella tularensis. Infect Immun (2008) 1.31
Approach to discover T- and B-cell antigens of intracellular pathogens applied to the design of Chlamydia trachomatis vaccines. Proc Natl Acad Sci U S A (2011) 1.27
Structural and functional analyses of the major outer membrane protein of Chlamydia trachomatis. J Bacteriol (2007) 1.21
The protective efficacy of chlamydial protease-like activity factor vaccination is dependent upon CD4+ T cells. Cell Immunol (2006) 1.16
Protection against an intranasal challenge by vaccines formulated with native and recombinant preparations of the Chlamydia trachomatis major outer membrane protein. Vaccine (2009) 1.15
Antibodies from women urogenitally infected with C. trachomatis predominantly recognized the plasmid protein pgp3 in a conformation-dependent manner. BMC Microbiol (2008) 1.10
Reduced live organism recovery and lack of hydrosalpinx in mice infected with plasmid-free Chlamydia muridarum. Infect Immun (2013) 1.10
Association of tubal factor infertility with elevated antibodies to Chlamydia trachomatis caseinolytic protease P. Am J Obstet Gynecol (2010) 1.09
CD4+ T cells and antibody are required for optimal major outer membrane protein vaccine-induced immunity to Chlamydia muridarum genital infection. Infect Immun (2010) 1.08
Porin activity of Anaplasma phagocytophilum outer membrane fraction and purified P44. J Bacteriol (2006) 1.08
A vault nanoparticle vaccine induces protective mucosal immunity. PLoS One (2009) 1.07
Oviduct infection and hydrosalpinx in DBA1/j mice is induced by intracervical but not intravaginal inoculation with Chlamydia muridarum. PLoS One (2013) 1.06
Immunization with the attenuated plasmidless Chlamydia trachomatis L2(25667R) strain provides partial protection in a murine model of female genitourinary tract infection. Vaccine (2009) 1.06
Identification of immunodominant antigens of Chlamydia trachomatis using proteome microarrays. Vaccine (2009) 1.05
Induction of cross-serovar protection against genital chlamydial infection by a targeted multisubunit vaccination approach. Clin Vaccine Immunol (2007) 1.04
Lack of long-lasting hydrosalpinx in A/J mice correlates with rapid but transient chlamydial ascension and neutrophil recruitment in the oviduct following intravaginal inoculation with Chlamydia muridarum. Infect Immun (2014) 1.01
Expression and porin activity of P28 and OMP-1F during intracellular Ehrlichia chaffeensis development. J Bacteriol (2008) 1.00
Chlamydia muridarum T cell antigens and adjuvants that induce protective immunity in mice. Infect Immun (2012) 0.98
Signaling via tumor necrosis factor receptor 1 but not Toll-like receptor 2 contributes significantly to hydrosalpinx development following Chlamydia muridarum infection. Infect Immun (2014) 0.94
Chlamydial protease-like activity factor--insights into immunity and vaccine development. J Reprod Immunol (2009) 0.94
A TLR2 agonist is a more effective adjuvant for a Chlamydia major outer membrane protein vaccine than ligands to other TLR and NOD receptors. Vaccine (2011) 0.92
Protection of wild-type and severe combined immunodeficiency mice against an intranasal challenge by passive immunization with monoclonal antibodies to the Chlamydia trachomatis mouse pneumonitis major outer membrane protein. Infect Immun (2008) 0.92
Induction of protective immunity against Chlamydia muridarum intracervical infection in DBA/1j mice. Vaccine (2013) 0.92
Induction of protective immunity against Chlamydia muridarum intravaginal infection with a chlamydial glycogen phosphorylase. PLoS One (2012) 0.91
Amphipols stabilize the Chlamydia major outer membrane protein and enhance its protective ability as a vaccine. Vaccine (2011) 0.91
Identification of immunodominant antigens by probing a whole Chlamydia trachomatis open reading frame proteome microarray using sera from immunized mice. Infect Immun (2010) 0.90
Complement factor C5 but not C3 contributes significantly to hydrosalpinx development in mice infected with Chlamydia muridarum. Infect Immun (2014) 0.89
Distinct roles of CD28- and CD40 ligand-mediated costimulation in the development of protective immunity and pathology during Chlamydia muridarum urogenital infection in mice. Infect Immun (2009) 0.89
Immunization with a combination of integral chlamydial antigens and a defined secreted protein induces robust immunity against genital chlamydial challenge. Infect Immun (2010) 0.88
Increased immunoaccessibility of MOMP epitopes in a vaccine formulated with amphipols may account for the very robust protection elicited against a vaginal challenge with Chlamydia muridarum. J Immunol (2014) 0.87
Management of Chlamydia trachomatis genital tract infection: screening and treatment challenges. Infect Drug Resist (2011) 0.86
Proteomic identification of immunodominant chlamydial antigens in a mouse model. J Proteomics (2012) 0.84
Intranasal vaccination with Chlamydia pneumoniae induces cross-species immunity against genital Chlamydia muridarum challenge in mice. PLoS One (2013) 0.84
Immunogenicity of a vaccine formulated with the Chlamydia trachomatis serovar F, native major outer membrane protein in a nonhuman primate model. Vaccine (2011) 0.84
Formulation, characterization, and expression of a recombinant MOMP Chlamydia trachomatis DNA vaccine encapsulated in chitosan nanoparticles. Int J Nanomedicine (2013) 0.82
Vaccination with the recombinant major outer membrane protein elicits antibodies to the constant domains and induces cross-serovar protection against intranasal challenge with Chlamydia trachomatis. Infect Immun (2013) 0.82
Chlamydia trachomatis recombinant MOMP encapsulated in PLGA nanoparticles triggers primarily T helper 1 cellular and antibody immune responses in mice: a desirable candidate nanovaccine. Int J Nanomedicine (2013) 0.81
Whole genome identification of C. trachomatis immunodominant antigens after genital tract infections and effect of antibiotic treatment of pigtailed macaques. J Proteomics (2014) 0.81
Induction of protection against vaginal shedding and infertility by a recombinant Chlamydia vaccine. Vaccine (2011) 0.81
A Multi-Component Prime-Boost Vaccination Regimen with a Consensus MOMP Antigen Enhances Chlamydia trachomatis Clearance. Front Immunol (2016) 0.80
Immunization with dendritic cells pulsed ex vivo with recombinant chlamydial protease-like activity factor induces protective immunity against genital chlamydiamuridarum challenge. Front Immunol (2011) 0.80
Enhancement of the protective efficacy of a Chlamydia trachomatis recombinant vaccine by combining systemic and mucosal routes for immunization. Vaccine (2010) 0.80
Antibody signature of spontaneous clearance of Chlamydia trachomatis ocular infection and partial resistance against re-challenge in a nonhuman primate trachoma model. PLoS Negl Trop Dis (2013) 0.80
Vaccination with major outer membrane protein proteosomes elicits protection in mice against a Chlamydia respiratory challenge. Microbes Infect (2013) 0.79
Biophysical and stabilization studies of the Chlamydia trachomatis mouse pneumonitis major outer membrane protein. Mol Pharm (2009) 0.79
Beyond "safe sex"--can we fight adolescent pelvic inflammatory disease? Eur J Pediatr (2012) 0.78
TRAIL-R1 is a negative regulator of pro-inflammatory responses and modulates long-term sequelae resulting from Chlamydia trachomatis infections in humans. PLoS One (2014) 0.78
Quantitative In Vivo Detection of Chlamydia muridarum Associated Inflammation in a Mouse Model Using Optical Imaging. Mediators Inflamm (2015) 0.77
Differences in infectivity and induction of infertility: a comparative study of Chlamydia trachomatis strains in the murine model. Microbes Infect (2012) 0.77
A vaccine formulated with a combination of TLR-2 and TLR-9 adjuvants and the recombinant major outer membrane protein elicits a robust immune response and significant protection against a Chlamydia muridarum challenge. Microbes Infect (2013) 0.77
Cell-free production of a functional oligomeric form of a chlamydia major outer membrane protein (MOMP) for vaccine development. J Biol Chem (2017) 0.76
Assessment of the role in protection and pathogenesis of the Chlamydia muridarum V-type ATP synthase subunit A (AtpA) (TC0582). Microbes Infect (2013) 0.76
A vaccine formulated with the major outer membrane protein can protect C3H/HeN, a highly susceptible strain of mice, from a Chlamydia muridarum genital challenge. Immunology (2015) 0.76
Chlamydia muridarum induction of glandular duct dilation in mice. Infect Immun (2015) 0.75
Phosphate substitution in an AlOOH - TLR4 adjuvant system (SPA08) modulates the immunogenicity of Serovar E MOMP from Chlamydia trachomatis. Hum Vaccin Immunother (2016) 0.75
MRI as a Novel In Vivo Approach for Assessing Structural Changes of Chlamydia Pathology in a Mouse Model. PLoS One (2016) 0.75
Chlamydial Type III Secretion System Needle Protein Induces Protective Immunity against Chlamydia muridarum Intravaginal Infection. Biomed Res Int (2017) 0.75
Update on Chlamydia trachomatis Vaccinology. Clin Vaccine Immunol (2017) 0.75
Comparison of the nine polymorphic membrane proteins of Chlamydia trachomatis for their ability to induce protective immune responses in mice against a C. muridarum challenge. Vaccine (2017) 0.75
Serovar-specific immune responses to peptides of variable regions of Chlamydia trachomatis major outer membrane protein in serovar D-infected women. Clin Exp Med (2008) 0.75
Tricine-sodium dodecyl sulfate-polyacrylamide gel electrophoresis for the separation of proteins in the range from 1 to 100 kDa. Anal Biochem (1987) 59.79
Purification and partial characterization of the major outer membrane protein of Chlamydia trachomatis. Infect Immun (1981) 18.13
New knowledge of chlamydiae and the diseases they cause. J Infect Dis (1975) 9.35
Mapping antigenic domains expressed by Chlamydia trachomatis major outer membrane protein genes. Proc Natl Acad Sci U S A (1988) 6.54
Diversity of Chlamydia trachomatis major outer membrane protein genes. J Bacteriol (1987) 6.16
Prevalence of chlamydial and gonococcal infections among young adults in the United States. JAMA (2004) 5.66
Pelvic inflammatory disease and fertility. A cohort study of 1,844 women with laparoscopically verified disease and 657 control women with normal laparoscopic results. Sex Transm Dis (1992) 5.19
Immunity to murine chlamydial genital infection. Infect Immun (2002) 4.64
AN UNIDENTIFIED VIRUS WHICH PRODUCES PNEUMONIA AND SYSTEMIC INFECTION IN MICE. Science (1942) 4.30
Chlamydial disease pathogenesis. The 57-kD chlamydial hypersensitivity antigen is a stress response protein. J Exp Med (1989) 4.25
High-resolution mapping of serovar-specific and common antigenic determinants of the major outer membrane protein of Chlamydia trachomatis. J Exp Med (1988) 3.55
Intravaginal inoculation of mice with the Chlamydia trachomatis mouse pneumonitis biovar results in infertility. Infect Immun (1994) 2.73
Immunity to murine Chlamydia trachomatis genital tract reinfection involves B cells and CD4(+) T cells but not CD8(+) T cells. Infect Immun (2000) 2.53
Vaccination against chlamydial genital tract infection after immunization with dendritic cells pulsed ex vivo with nonviable Chlamydiae. J Exp Med (1998) 2.19
Purification and partial characterization of the opacity-associated proteins of Neisseria gonorrhoeae. J Exp Med (1984) 2.16
Protective role of magnesium in the neutralization by antibodies of Chlamydia trachomatis infectivity. Infect Immun (1988) 2.11
Progesterone favors the development of human T helper cells producing Th2-type cytokines and promotes both IL-4 production and membrane CD30 expression in established Th1 cell clones. J Immunol (1995) 1.99
Population-based genetic and evolutionary analysis of Chlamydia trachomatis urogenital strain variation in the United States. J Bacteriol (2004) 1.94
The potential for vaccine against infection of the genital tract with Chlamydia trachomatis. Sex Transm Dis (1999) 1.84
CLASSIFICATION OF TRACHOMA VIRUS STRAINS BY PROTECTION OF MICE FROM TOXIC DEATH. J Immunol (1963) 1.83
CpG DNA induces stronger immune responses with less toxicity than other adjuvants. Vaccine (2000) 1.80
Heterotypic protection of mice against chlamydial salpingitis and colonization of the lower genital tract with a human serovar F isolate of Chlamydia trachomatis by prior immunization with recombinant serovar L1 major outer-membrane protein. J Gen Microbiol (1992) 1.77
Resolution of secondary Chlamydia trachomatis genital tract infection in immune mice with depletion of both CD4+ and CD8+ T cells. Infect Immun (2001) 1.61
Aluminium adjuvants--in retrospect and prospect. Vaccine (2004) 1.60
Disulfide cross-linked envelope proteins: the functional equivalent of peptidoglycan in chlamydiae? J Bacteriol (1996) 1.58
Protection against infertility in a BALB/c mouse salpingitis model by intranasal immunization with the mouse pneumonitis biovar of Chlamydia trachomatis. Infect Immun (1994) 1.54
Immunization with an acellular vaccine consisting of the outer membrane complex of Chlamydia trachomatis induces protection against a genital challenge. Infect Immun (1997) 1.51
Prolonged exposure to progesterone prevents induction of protective mucosal responses following intravaginal immunization with attenuated herpes simplex virus type 2. J Virol (2003) 1.46
Effects of estradiol and progesterone on susceptibility and early immune responses to Chlamydia trachomatis infection in the female reproductive tract. Infect Immun (2000) 1.42
Immunogenicity of a chimeric peptide corresponding to T helper and B cell epitopes of the Chlamydia trachomatis major outer membrane protein. J Exp Med (1992) 1.41
A new computer model for estimating the impact of vaccination protocols and its application to the study of Chlamydia trachomatis genital infections. Vaccine (1995) 1.35
DNA vaccination with the major outer-membrane protein gene induces acquired immunity to Chlamydia trachomatis (mouse pneumonitis) infection. J Infect Dis (1997) 1.34
Immunization with the Chlamydia trachomatis mouse pneumonitis major outer membrane protein can elicit a protective immune response against a genital challenge. Infect Immun (2001) 1.31
Transcutaneous immunization with combined cholera toxin and CpG adjuvant protects against Chlamydia muridarum genital tract infection. Infect Immun (2004) 1.30
Differential regulation of CD4 lymphocyte recruitment between the upper and lower regions of the genital tract during Chlamydia trachomatis infection. Infect Immun (2000) 1.26
Prior genital tract infection with a murine or human biovar of Chlamydia trachomatis protects mice against heterotypic challenge infection. Infect Immun (1999) 1.25
Vaccination of mice with DNA plasmids coding for the Chlamydia trachomatis major outer membrane protein elicits an immune response but fails to protect against a genital challenge. Vaccine (1999) 1.25
Oral immunization with chlamydial major outer membrane protein (MOMP). Invest Ophthalmol Vis Sci (1988) 1.25
Priming with Chlamydia trachomatis major outer membrane protein (MOMP) DNA followed by MOMP ISCOM boosting enhances protection and is associated with increased immunoglobulin A and Th1 cellular immune responses. Infect Immun (2000) 1.23
Partial protection against genital reinfection by immunization of guinea-pigs with isolated outer-membrane proteins of the chlamydial agent of guinea-pig inclusion conjunctivitis. J Gen Microbiol (1993) 1.23
Vaccines for Chlamydia trachomatis infections. Curr Opin Investig Drugs (2002) 1.22
Immunization with the Chlamydia trachomatis mouse pneumonitis major outer membrane protein by use of CpG oligodeoxynucleotides as an adjuvant induces a protective immune response against an intranasal chlamydial challenge. Infect Immun (2002) 1.15
Abrogation of attenuated lentivirus-induced protection in rhesus macaques by administration of depo-provera before intravaginal challenge with simian immunodeficiency virus mac239. J Infect Dis (2004) 1.11
Prediction of the membrane-spanning beta-strands of the major outer membrane protein of Chlamydia. Protein Sci (2002) 1.10
Characterization of the disulfide bonds and free cysteine residues of the Chlamydia trachomatis mouse pneumonitis major outer membrane protein. Biochemistry (2005) 1.05
Chlamydia vaccines: strategies and status. BioDrugs (2002) 1.05
Chlamydia trachomatis infection in the female reproductive tract of the rat: influence of progesterone on infectivity and immune response. Infect Immun (1998) 1.00
Chlamydia trachomatis infection in asymptomatic men. Am J Prev Med (2003) 0.93
Characterization of the humoral response induced by a peptide corresponding to variable domain IV of the major outer membrane protein of Chlamydia trachomatis serovar E. Infect Immun (1992) 0.90
Prevalence and significance of fluoroquinolone resistant Escherichia coli in patients undergoing transrectal ultrasound guided prostate needle biopsy. J Urol (2011) 2.95
Imaging of effector memory T cells during a delayed-type hypersensitivity reaction and suppression by Kv1.3 channel block. Immunity (2008) 2.23
Prevalence of ST131 among fluoroquinolone-resistant Escherichia coli obtained from rectal swabs before transrectal prostate biopsy. Urology (2013) 1.49
MyD88 is pivotal for the early inflammatory response and subsequent bacterial clearance and survival in a mouse model of Chlamydia pneumoniae pneumonia. J Biol Chem (2005) 1.47
Screening rectal culture to identify fluoroquinolone-resistant organisms before transrectal prostate biopsy: do the culture results between office visit and biopsy correlate? Urology (2013) 1.42
Chlamydia trachomatis native major outer membrane protein induces partial protection in nonhuman primates: implication for a trachoma transmission-blocking vaccine. J Immunol (2009) 1.33
Up-regulation of the JAK/STAT1 signal pathway during Chlamydia trachomatis infection. J Immunol (2005) 1.22
TLR/MyD88 and liver X receptor alpha signaling pathways reciprocally control Chlamydia pneumoniae-induced acceleration of atherosclerosis. J Immunol (2008) 1.22
Vaccines for Chlamydia trachomatis infections. Curr Opin Investig Drugs (2002) 1.22
Structural and functional analyses of the major outer membrane protein of Chlamydia trachomatis. J Bacteriol (2007) 1.21
Reversal of the antichlamydial activity of putative type III secretion inhibitors by iron. Infect Immun (2007) 1.20
Immunization with the Chlamydia trachomatis mouse pneumonitis major outer membrane protein by use of CpG oligodeoxynucleotides as an adjuvant induces a protective immune response against an intranasal chlamydial challenge. Infect Immun (2002) 1.15
Protection against an intranasal challenge by vaccines formulated with native and recombinant preparations of the Chlamydia trachomatis major outer membrane protein. Vaccine (2009) 1.15
Prediction of the membrane-spanning beta-strands of the major outer membrane protein of Chlamydia. Protein Sci (2002) 1.10
Temporal expression of type III secretion genes of Chlamydia pneumoniae. Infect Immun (2003) 1.10
Chlorhexidine and mupirocin susceptibilities of methicillin-resistant staphylococcus aureus from colonized nursing home residents. Antimicrob Agents Chemother (2012) 1.06
Interaction between components of the type III secretion system of Chlamydiaceae. J Bacteriol (2005) 1.06
Identification of immunodominant antigens of Chlamydia trachomatis using proteome microarrays. Vaccine (2009) 1.05
Characterization of the disulfide bonds and free cysteine residues of the Chlamydia trachomatis mouse pneumonitis major outer membrane protein. Biochemistry (2005) 1.05
Protection of mice from a Chlamydia trachomatis vaginal infection using a Salicylidene acylhydrazide, a potential microbicide. J Infect Dis (2011) 1.04
Candidate vaginal microbicides with activity against Chlamydia trachomatis and Neisseriagonorrhoeae. Int J Antimicrob Agents (2010) 0.99
New murine model for the study of Chlamydia trachomatis genitourinary tract infections in males. Infect Immun (2004) 0.98
Detection of fluoroquinolone-resistant organisms from rectal swabs by use of selective media prior to a transrectal prostate biopsy. J Clin Microbiol (2010) 0.98
Pre-clinical pharmacokinetics and anti-chlamydial activity of salicylidene acylhydrazide inhibitors of bacterial type III secretion. J Antibiot (Tokyo) (2012) 0.93
A TLR2 agonist is a more effective adjuvant for a Chlamydia major outer membrane protein vaccine than ligands to other TLR and NOD receptors. Vaccine (2011) 0.92
Promoters for Chlamydia type III secretion genes show a differential response to DNA supercoiling that correlates with temporal expression pattern. J Bacteriol (2010) 0.92
Protection of wild-type and severe combined immunodeficiency mice against an intranasal challenge by passive immunization with monoclonal antibodies to the Chlamydia trachomatis mouse pneumonitis major outer membrane protein. Infect Immun (2008) 0.92
Comparison of two commercially available selective media to screen for vancomycin-resistant enterococci. Am J Clin Pathol (2002) 0.92
Amphipols stabilize the Chlamydia major outer membrane protein and enhance its protective ability as a vaccine. Vaccine (2011) 0.91
Identification of immunodominant antigens by probing a whole Chlamydia trachomatis open reading frame proteome microarray using sera from immunized mice. Infect Immun (2010) 0.90
Comparison of medium, temperature, and length of incubation for detection of vancomycin-resistant Enterococcus. J Clin Microbiol (2012) 0.88
Role of matrix metalloproteinase-7 in the modulation of a Chlamydia trachomatis infection. Immunology (2006) 0.87
Proteomic identification of immunodominant chlamydial antigens in a mouse model. J Proteomics (2012) 0.84
Comparison of broth enhancement to direct plating for screening of rectal cultures for ciprofloxacin-resistant Escherichia coli. J Clin Microbiol (2012) 0.84
Immunogenicity of a vaccine formulated with the Chlamydia trachomatis serovar F, native major outer membrane protein in a nonhuman primate model. Vaccine (2011) 0.84
Induction of protection in mice against a respiratory challenge by a vaccine formulated with the Chlamydia major outer membrane protein adjuvanted with IC31®. Vaccine (2011) 0.83
Toll-like receptor 2-dependent activity of native major outer membrane protein proteosomes of Chlamydia trachomatis. Infect Immun (2012) 0.83
Induction of protective immunity against a Chlamydia trachomatis genital infection in three genetically distinct strains of mice. Immunology (2003) 0.82
Vaccination with the recombinant major outer membrane protein elicits antibodies to the constant domains and induces cross-serovar protection against intranasal challenge with Chlamydia trachomatis. Infect Immun (2013) 0.82
CHROMagar Candida medium for direct susceptibility testing of yeast from blood cultures. J Clin Microbiol (2005) 0.81
Induction of protection against vaginal shedding and infertility by a recombinant Chlamydia vaccine. Vaccine (2011) 0.81
A 3-dimensional trimeric β-barrel model for Chlamydia MOMP contains conserved and novel elements of Gram-negative bacterial porins. PLoS One (2013) 0.80
C3H male mice with severe combined immunodeficiency cannot clear a urethral infection with a human serovar of Chlamydia trachomatis. Infect Immun (2009) 0.80
Enhancement of the protective efficacy of a Chlamydia trachomatis recombinant vaccine by combining systemic and mucosal routes for immunization. Vaccine (2010) 0.80
Biophysical and stabilization studies of the Chlamydia trachomatis mouse pneumonitis major outer membrane protein. Mol Pharm (2009) 0.79
Vaccination with major outer membrane protein proteosomes elicits protection in mice against a Chlamydia respiratory challenge. Microbes Infect (2013) 0.79
Vaccination of newborn mice induces a strong protective immune response against respiratory and genital challenges with Chlamydia trachomatis. Vaccine (2005) 0.78
Differences in infectivity and induction of infertility: a comparative study of Chlamydia trachomatis strains in the murine model. Microbes Infect (2012) 0.77
A vaccine formulated with a combination of TLR-2 and TLR-9 adjuvants and the recombinant major outer membrane protein elicits a robust immune response and significant protection against a Chlamydia muridarum challenge. Microbes Infect (2013) 0.77
Mechanism of T-cell mediated protection in newborn mice against a Chlamydia infection. Microbes Infect (2013) 0.77
Maternal immunity partially protects newborn mice against a Chlamydia trachomatis intranasal challenge. J Reprod Immunol (2010) 0.76
Long-term stability of a vaccine formulated with the amphipol-trapped major outer membrane protein from Chlamydia trachomatis. J Membr Biol (2014) 0.76
Inclusion fluorescent-antibody test as a screening assay for detection of antibodies to Chlamydia pneumoniae. Clin Diagn Lab Immunol (2002) 0.75
A new murine model for testing vaccines against genital Chlamydia trachomatis infections in males. Vaccine (2010) 0.75
Microbiological sampling of the forgotten components of a flexible fiberoptic laryngoscope: what lessons can we learn? Otolaryngol Head Neck Surg (2013) 0.75
Computational modeling of TC0583 as a putative component of the Chlamydia muridarum V-type ATP synthase complex and assessment of its protective capabilities as a vaccine antigen. Microbes Infect (2015) 0.75
Medical School Applicant Characteristics Associated With Performance in Multiple Mini-Interviews Versus Traditional Interviews: A Multi-Institutional Study. Acad Med (2017) 0.75
Protective effect of methicillin-susceptible Staphylococcus aureus carriage against methicillin-resistant S. aureus acquisition in nursing homes: a prospective cross-sectional study. Infect Control Hosp Epidemiol (2014) 0.75